A detailed history of Bank Of New Hampshire transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bank Of New Hampshire holds 7,132 shares of BMY stock, worth $400,961. This represents 0.09% of its overall portfolio holdings.

Number of Shares
7,132
Previous 10,972 35.0%
Holding current value
$400,961
Previous $455,000 18.9%
% of portfolio
0.09%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$39.66 - $51.75 $152,294 - $198,720
-3,840 Reduced 35.0%
7,132 $369,000
Q2 2024

Jul 01, 2024

SELL
$40.25 - $52.99 $5,031 - $6,623
-125 Reduced 1.13%
10,972 $455,000
Q1 2024

Apr 10, 2024

SELL
$47.98 - $54.4 $78,927 - $89,488
-1,645 Reduced 12.91%
11,097 $601,000
Q4 2023

Feb 02, 2024

SELL
$48.48 - $57.85 $534,007 - $637,217
-11,015 Reduced 46.37%
12,742 $653,000
Q3 2023

Oct 10, 2023

SELL
$57.89 - $64.73 $231 - $258
-4 Reduced 0.02%
23,757 $1.38 Million
Q2 2023

Jul 28, 2023

SELL
$63.71 - $70.74 $7,645 - $8,488
-120 Reduced 0.5%
23,761 $1.52 Million
Q1 2023

Apr 04, 2023

BUY
$65.71 - $74.53 $15,770 - $17,887
240 Added 1.02%
23,881 $1.66 Million
Q4 2022

Jan 10, 2023

BUY
$68.48 - $81.09 $61,084 - $72,332
892 Added 3.92%
23,641 $1.7 Million
Q3 2022

Oct 24, 2022

BUY
$0.13 - $76.84 $22 - $13,293
173 Added 0.77%
22,749 $1.62 Million
Q2 2022

Jul 08, 2022

BUY
$72.62 - $79.98 $537,242 - $591,692
7,398 Added 48.74%
22,576 $1.74 Million
Q1 2022

Apr 20, 2022

BUY
$61.48 - $73.72 $54,102 - $64,873
880 Added 6.15%
15,178 $1.11 Million
Q4 2021

Jan 12, 2022

BUY
$53.63 - $62.52 $100,019 - $116,599
1,865 Added 15.0%
14,298 $892,000
Q2 2021

Jul 06, 2021

BUY
$61.91 - $67.42 $769,727 - $838,232
12,433 New
12,433 $831,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bank Of New Hampshire Portfolio

Follow Bank Of New Hampshire and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New Hampshire, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New Hampshire with notifications on news.